BSI-201: Lead Product and Clinical Stage PARP Inhibitor (IV)
BSI-201, a potential first and best-in-class Poly (ADP-ribose) polymerase (PARP) inhibitor, is now in multiple Phase 2 trials as both a single agent and in combination with traditional chemotherapy. We have key clinical programs in the following cancers: ovarian, breast, brain and uterine. BSI-201 has shown an excellent clinical safety profile in Phase 1 studies.
BSI-201 Lead Product Profile and Differentiation- Small molecule (MV<300)
- Targets PARP-1
- Wide therapeutic window
- IV infusion, two times per week
- Strong safety database of >100 patients:
- Monotherapy and in combination with cytotoxic chemotherapy
- Points of differentiation:
- Multiple genomics-driven Phase 2 indications
- First PARP program in randomized Phase 2 study
- Prolonged inhibition of PARP activity = enhanced potency
- Active in vivo when administered: IV, IP, SC or oral
- Penetrates blood-brain barrier
- Active in drug-resistant tumors
- Demonstrated synergy in human tumor xenografts with:
- Topetecan
- Carboplatin/Paclitaxel
- Temozolomide
Learn more about the candidates in our PARP Inhibitor Program:
Learn more about our BSI-301: Preclinical Stage Iodothyronine Anti-tubulin Program.